Rebound weight gain

Rebound weight gain is what happens after stopping a GLP-1. It is not a rumor or a failure of willpower — it is one of the best-documented findings in the whole field, because the trials were designed specifically to measure it.

STEP 4 ran a 20-week semaglutide run-in during which participants lost a mean 10.6%, then randomized them to continue or switch to placebo. Over the following 48 weeks, those who continued lost a further 7.9%; those on placebo regained 6.9%. SURMOUNT-4 did the same with tirzepatide on a larger scale: after a 36-week lead-in averaging 20.9% loss, continuing produced another 5.5% of loss while placebo produced a 14.0% gain. Of those who continued, 89.5% held at least 80% of their lead-in loss, against 16.6% of those who stopped.

The mechanism is not mysterious. These drugs work while they are in your system and stop working when they are not. Appetite signaling returns, gastric emptying normalizes, and the reduced calorie needs of a lighter body remain — a combination that favors regain. The same pattern follows stopping a blood pressure drug, without anyone calling it a moral failure.

This reframes what a GLP-1 prescription is. It is closer to ongoing treatment for a chronic condition than to a course of antibiotics, and the labels describe the weight indications as reducing excess body weight and maintaining weight reduction long term. That phrasing is deliberate.

The practical questions are financial and clinical at once. Ask your prescriber what the long-term plan is, whether a maintenance dose lower than your peak is reasonable, and what a structured taper would look like if you need to stop. Ask your insurer whether coverage continues after you reach a goal weight — some plans stop paying at exactly the wrong moment. Our maintenance and step-down protocol and rebound mechanism review cover the options.